BPM31543 (calcitrol) is a first-in-class topical compound currently in clinical development for the treatment of chemotherapy-induced hair loss (alopecia).

BPM31543 manipulates gene expression in hair follicles, keeping cells in the growth phase and making them resistant to chemotoxic agents.

BPM31543 has appeared to show promising results in an early phase study.

BPM31543 in clinical development

Chemotherapy-Induced Alopecia | Topical

  • Discovery Complete
  • Preclinical Complete
  • Phase 1 Complete
  • Phase 2
  • Phase 3
This Phase I trial has been completed. This was a dose escalation study to determine maximum tolerated dose and the overall safety and tolerability of topical compound 31543 (Calcitriol) in patients receiving taxane-based chemotherapy regimen. The trial also evaluated the potential effectiveness of calcitriol in preventing and/or diminishing chemotherapy-induced alopecia. Clinical sites included Memorial Sloan Kettering Cancer Center and Cedars Sinai Medical Center.